Soleno Therapeutics, Inc. (SLNO)
Automate Your Wheel Strategy on SLNO
With Tiblio's Option Bot, you can configure your own wheel strategy including SLNO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SLNO
- Rev/Share 0.0
- Book/Share 5.0296
- PB 15.3869
- Debt/Equity 0.0127
- CurrentRatio 19.6373
- ROIC -0.5366
- MktCap 3899983921.0
- FreeCF/Share -1.9388
- PFCF -43.5597
- PE -18.0289
- Debt/Assets 0.0093
- DivYield 0
- ROE -0.7752
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 2
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | SLNO | Stifel | -- | Buy | -- | $74 | March 5, 2025 |
| Initiation | SLNO | H.C. Wainwright | -- | Buy | -- | $70 | Sept. 3, 2024 |
News
Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Soleno's Marketing Authorization Application (MAA) seeking regulatory approval of Diazoxide Choline Prolonged-Release Tablets (previously referred to as DCCR) for the treatment of adults and children four years and older with Prader-Willi syndrome (PWS) who have hyperphagia had been validated by the European Medicines Agency (EMA).
Read More
Soleno Therapeutics, Inc. (SLNO) Q1 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Soleno Therapeutics, Inc. (NASDAQ:SLNO ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors Anish Bhatnagar - Chief Executive Officer Meredith Manning - Chief Commercial Officer Jim Mackaness - Chief Financial Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Debjit Chattopadhyay - Guggenheim Securities Kristen Kluska - Cantor Leland Gershell - Oppenheimer Brian Skorney - Baird James Condulis - Stifel Myriam Belghiti - LifeSci Capital Yale Jen - Laidlaw Operator Greetings, and welcome to the Soleno Therapeutics First Quarter 2025 Earnings Conference Call. At this time, note that all participants …
Read More
Soleno Therapeutics (SLNO) is on the Move, Here's Why the Trend Could be Sustainable
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Soleno Therapeutics (SLNO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Read More
Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26 th , at 5:30pm ET REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved VYKAT XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS).
Read More
About Soleno Therapeutics, Inc. (SLNO)
- IPO Date 2014-11-13
- Website https://soleno.life
- Industry Biotechnology
- CEO Dr. Anish Bhatnagar M.D.
- Employees 115